Top Story Today
The COVID Company Just Became a Cancer Company
Moderna and Merck's personalized mRNA cancer vaccine hit both primary and key secondary endpoints in a Phase 3 melanoma trial, marking the first time any mRNA cancer therapy has succeeded in a late-stage study. Moderna's market cap surged roughly $45 billion in a single session. The vaccine works by sequencing each patient's tumor DNA, identifying up to 34 unique molecular fingerprints, then manufacturing a custom mRNA shot that trains the immune system to hunt remaining cancer cells after surgery. Barclays estimates the melanoma indication alone could generate $3 billion in annual sales by 2035.
Why it matters: This result transforms the mRNA platform from a one-pandemic-wonder into a validated oncology technology, with a second Phase 3 trial already running in lung cancer and a potential path to treating any solid tumor with identifiable neoantigens.
Read more →Deals and M&A
Lilly Just Dropped $3.8 Billion on Psychedelic Medicine
Eli Lilly is acquiring AtaiBeckley and its psychedelic-derived depression drugs for up to $3.8 billion, the biggest bet Big Pharma has ever placed on psychedelics. The lead asset, a synthetic toad-venom compound delivered as a nasal spray, showed statistically significant depression relief within 24 hours in mid-stage trials. About $1 billion of the price tag is tied to milestones, meaning Lilly hedged its optimism with receipts.
Read more →PTC Scooped a Gene Therapy Out of Bankruptcy for $211M
PTC Therapeutics won a bankruptcy auction for Sangamo's Fabry disease gene therapy, paying $111 million upfront with $100 million more tied to FDA approval. The asset already has a BLA submission on track for Q4 2026, targeting a $2.7 billion market where patients currently endure biweekly IV infusions for life.
Read more →Repligen Buys Cell Therapy's Cold Chain for $1.5 Billion
Repligen is acquiring BioLife Solutions, whose biopreservation media is already embedded in 17 commercial cell and gene therapies and 250 active clinical trials. The $1.5 billion deal (64% stock, 36% cash) fills a major gap in Repligen's portfolio and bets that CGT manufacturing infrastructure will be a defining growth story in bioprocessing.
Read more →Clinical and Competitive
Two Underdogs Just Crashed J&J's Lung Cancer Party
Taiho and Cullinan's oral EGFR inhibitor zipalertinib hit its primary endpoint in a Phase 3 first-line lung cancer trial, challenging J&J's Rybrevant in the exon 20 insertion space. The safety board recommended unblinding the study early, a signal that the benefit may exceed the 40% risk-reduction threshold the trial was designed to detect.
Read more →Lilly Drops $750M on a Pen Factory (Yes, a Pen)
Lilly invested $750 million with manufacturing partner Resilience to massively expand KwikPen production for Zepbound and Mounjaro near Cincinnati. Despite committing over $50 billion to manufacturing since 2020, Lilly still can't keep up with GLP-1 demand. The expansion adds 400 jobs and should be fully operational by early 2027.
Read more →Regulatory and Preparedness
The FDA Commissioner Allegedly Tried to Kill a Rare Disease Drug
Endpoints News reported that FDA Commissioner Marty Makary personally sought to reject KalVista's first-in-class oral treatment for hereditary angioedema, an almost unheard-of level of commissioner intervention in individual drug decisions. Senior officials reportedly pushed back on legal grounds. The drug was approved 16 days late on July 3, 2025, but the episode adds to growing concerns about politicization at the agency.
Read more →A Seal in Australia Just Became a Bird Flu Warning Sign
Australia confirmed H5N1 bird flu in a local mammal for the first time: a long-nosed fur seal found on a South Australian beach. Every mammalian infection gives the virus practice replicating in cells that look more like ours. Australia's pandemic vaccine readiness leans on CSL's platform, which is designed to rapidly release adapted doses after strain selection.
Read more →